-
Medtronic Kanghui and Changzhou High-Tech Zone Partner on Science Park
•
Medtronic Kanghui and Changzhou National High-Tech Industrial Development Zone have agreed to collaborate on the establishment of the “Medtronic Kanghui Changzhou Science and Technology Park.” The initiative aims to enhance regional advanced medical manufacturing capabilities, particularly in the orthopedic industry. Background and Strategic RoleKanghui became a wholly-owned subsidiary of Medtronic…
-
NHC Releases Technical Guidelines for Drug Clinical Evaluation
•
The National Health Commission (NHC) has released the “Technical Guidelines for Comprehensive Clinical Evaluation of Cardiovascular Drugs,” “Technical Guidelines for Comprehensive Clinical Evaluation of Antineoplastic Drugs,” and “Technical Guidelines for Comprehensive Clinical Evaluation of Children’s Drugs” (all 2022 trial versions), effective as of July 1, 2022. BackgroundThe NHC released the…
-
HitGen and Haichang Bio Partner to Develop Anti-Cancer RNAi Drugs
•
China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm Zhejiang Haichang Biotechnology Co., Ltd, an RNA interference (RNAi) specialist, to develop anti-cancer RNAi drugs. The partnership aims to leverage the strengths of both companies in RNAi drug discovery and delivery systems. Company ProfilesHitGen, focused…
-
Hainan Medical Products Administration Issues Guidelines for Imported Drug Management
•
The Hainan Medical Products Administration (HMPA) has released a set of guidelines that took effect immediately, providing measures for the management of patients accessing imported drugs through the Hainan Free Trade Port Boao Lecheng International Medical Tourism Pilot Zone. The guidelines focus on managing patients who travel to Hainan to…
-
Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a Phase I clinical study for its ABSK061, an oral highly selective FGFR2/3 inhibitor, in solid tumors. The molecule is described as the first of its kind globally to reach the clinical stages. Study DetailsThe study,…
-
Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide
•
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in a clinical study for its PD-L1 antibody ASC22 (envafolimab) in combination with chidamide for the functional cure of human immunodeficiency virus (HIV) infection. The study was initiated by the Shanghai Public Health Clinical Center. This…
-
Fosun Pharmaceutical and ReNeuron Renew CTX Cell Therapy Deal for China
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has negotiated a new “supplemental terms agreement” with UK-based partner ReNeuron Group plc (OTCMKTS: RNUGF) worth GBP 6 million (USD 7.3 million). This deal builds on an earlier agreement signed in April 2019, under which Fosun obtained exclusive development,…
-
Eurofins DiscoverX Opens Shanghai Office to Expand Asia-Pacific Operations
•
California-based Eurofins DiscoverX Products LLC, a manufacturer of drug discovery solutions, announced the opening of an office in Shanghai, China. The establishment of Eurofins DiscoverX (Shanghai) Ltd marks the company’s first direct expansion of its Asia-Pacific operations into the mainland China market. The new office will serve as a base…
